Global Gene Therapy Market is Projected to Reach USD 13.0 Billion by 2024 from USD 3.8 Billion in 2019, at a CAGR of 27.8% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 5, 2020--
The “Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering.
High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market
The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. In addition, the strong product pipeline of market players is expected to offer significant growth opportunities in the coming years. However, the high cost of treatment is expected to hamper the market growth to a certain extent in the coming years.
Neurological diseases segment accounted for the largest share of the gene therapy market, by indication, in 2018
Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. This can be attributed to the increasing number of gene therapy products being approved for the treatment of neurological diseases and the high market penetration of oligonucleotide-based gene therapies.
Viral vectors segment to register the highest growth in the gene therapy market during the forecast period
The gene therapy market, by vector, has been segmented into viral and non-viral vectors. In 2018, the non-viral vectors segment accounted for the largest share of this market. However, the viral vectors segment is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing demand for CAR T-based gene therapies and the rising incidence of cancer.
North America will continue to dominate the gene therapy market during the forecast period
Geographically, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the gene therapy market, followed by Europe. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.
Key Benefits of Buying the Report:
This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. Also, this report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.
Key Topics Covered:
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Research Data
2.2 Secondary Data
2.3 Primary Data
2.4 Market Size Estimation
2.5 Market Breakdown and Data Triangulation
2.6 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Gene Therapy Market Overview
4.2 North America: Market, By Vector (2018)
4.3 Geographical Snapshot of the Market
5 Market Overview
5.2 Market Dynamics
126.96.36.199 High Incidence of Cancer and Other Target Diseases
188.8.131.52 Product Approvals
184.108.40.206 Funding for Gene Therapy Research
220.127.116.11 Strong Product Pipeline
18.104.22.168 High Cost of Treatments
6 Gene Therapy Market, By Vector
6.2 Non-Viral Vectors
6.3 Viral Vectors
7 Gene Therapy Market, By Indication
7.2 Neurological Diseases
7.4 Hepatological Diseases
7.5 Duchenne Muscular Dystrophy
7.6 Other Indications
8 Gene Therapy Market, By Delivery Method
8.2 In Vivo Gene Therapy
8.3 Ex Vivo Gene Therapy
9 Gene Therapy Market, By Region
9.2 North America
9.4 Asia Pacific
9.5 Rest of the World
10 Competitive Landscape
10.2 Market Share Analysis, 2018
10.3 Key Strategies
10.4 Competitive Leadership Mapping (2018)
10.4.1 Visionary Leaders
10.4.3 Dynamic Differentiators
10.4.4 Emerging Companies
11 Company Profiles
11.2 Gilead Sciences, Inc.
11.3 Amgen, Inc.
11.4 Novartis AG
11.5 Orchard Therapeutics Plc
11.6 Spark Therapeutics, Inc. (A Part of Hoffmann-La Roche)
11.7 Molmed S.P.A.
11.8 Anges, Inc.
11.9 Bluebird Bio, Inc.
11.10 Human Stem Cells Institute (HSCI)
11.11 SIBIONO Genetech Co., Ltd.
11.12 Shanghai Sunway Biotech Co., Ltd
11.13 Uniqure N.V.
11.14 Gensight Biologics S.A.
11.15 Celgene Corporation (A Bristol-Myers Squibb Company)
11.17 Sangamo Therapeutics
11.18 Mustang Bio
11.19 AGTC (Applied Genetic Technologies Corporation)
11.20 Poseida Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/xhxwrm
View source version on businesswire.com:https://www.businesswire.com/news/home/20200205005314/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 02/05/2020 05:24 AM/DISC: 02/05/2020 05:24 AM